Ownership history in UBS Group AG · 4 quarters on record
This page tracks every 13F SEC filing in which UBS Group AG reported a position in KAIROS PHARMA LTD (KAPA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | REDUCED | 5,979 | -3,479 | -36.8% | 0.00% | $7K | $1.17 |
| 2025 Q2 | ADDED | 9,458 | +6,666 | +238.8% | 0.00% | $7K | $0.71 |
| 2025 Q1 | REDUCED | 2,792 | -8,053 | -74.3% | 0.00% | $3K | $0.94 |
| 2024 Q4 | INITIATED | 10,845 | — | — | 0.00% | $16K | $1.52 |
As of 2025 Q4 — sorted by position size